Inclusion Criteria:

          -  Have previously untreated and pathologically confirmed resectable Stage II, IIIA, or
             IIIB (N2) NSCLC.

          -  Be able to undergo protocol therapy, including necessary surgery. A positron emission
             tomography (PET) scan may be utilized as a surrogate for pathologic staging of N1
             lymph nodes for participants with T2b and T4 tumors.

          -  If male, must agree to use contraception or practice abstinence as well as refrain
             from donating sperm for at least 180 days after the last dose of neoadjuvant
             cisplatin.

          -  If female, may participate if not pregnant or breastfeeding, and at least one of the
             following conditions apply: 1) not a woman of childbearing potential (WOCBP); or 2) a
             WOCBP who agrees to follow contraceptive guidance during the treatment period and for
             at least 180 days after the last dose of study treatment.

          -  Have available formalin-fixed paraffin embedded (FFPE) tumor tissue sample blocks for
             submission. If blocks are not available, have unstained slides for submission for
             central programmed death-ligand 1 (PD-L1) testing.

          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within
             10 days of randomization.

          -  Have adequate organ function.

        Exclusion Criteria:

          -  A WOCBP who has a positive urine pregnancy test within 24 hours before the first dose
             of study treatment.

          -  Has one of the following tumor locations/types:1) NSCLC involving the superior sulcus;
             2) Large cell neuro-endocrine cancer (LCNEC); or 3) Sarcomatoid tumor.

          -  Has a history of (non-infectious) pneumonitis /interstitial lung disease that required
             steroids or has current pneumonitis/interstitial lung disease that requires steroids.

          -  Has an active infection requiring systemic therapy.

          -  Has had an allogenic tissue/sold organ transplant.

          -  Has a known severe hypersensitivity (≥ Grade 3) to pembrolizumab, its active substance
             and/or any of its excipients.

          -  Has a known severe hypersensitivity (≥ Grade 3) to any of the study chemotherapy
             agents and/or to any of their excipients.

          -  Has an active autoimmune disease that has required systemic treatment in past 2 years.

          -  Has a known history of human immunodeficiency virus (HIV) infection.

          -  Has a known history of Hepatitis B or Hepatitis C.

          -  Has a known history of active tuberculosis.

          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the trial, interfere with the participant's
             participation for the full duration of the trial, or is not in the best interest of
             the participant to participate.

          -  Has known psychiatric or substance abuse disorders that would interfere with
             cooperating with the requirements of the trial.

          -  Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with
             an agent directed to another co-inhibitory T-cell receptor.

          -  Has received prior systemic anti-cancer therapy including investigational agents for
             the current malignancy prior to randomization/allocation.

          -  Has received prior radiotherapy within 2 weeks of start of trial treatment.

          -  Has received a live vaccine within 30 days prior to the first dose of trial drug.

          -  Is currently participating in or has participated in a trial of an investigational
             agent or has used an investigational device within 4 weeks prior to the first dose of
             trial treatment.

          -  Has a diagnosis of immunodeficiency or is receiving either systemic steroid therapy or
             any other form of immunosuppressive therapy within 7 days prior the first dose of
             trial drug.

          -  Has a known additional malignancy that is progressing or requires active treatment
             within the past 5 years.

          -  Is pregnant or breastfeeding or expecting to conceive or father children within the
             projected duration of the trial, starting with the screening visit through 180 days
             after the last dose of trial treatment.